BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Euronext Paris 12:30:00 2024-07-15 pm EDT | ||
| 6.783 EUR | -2.08% |
|
| Current month | -3.49% | ||
| 1 month | -6.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 6.783 | -2.08% |
| 24-07-12 | 6.927 | +2.61% |
| 24-07-11 | 6.751 | +1.02% |
| 24-07-10 | 6.683 | +1.50% |
| 24-07-09 | 6.584 | -1.08% |
Real-time Euronext Paris
Last update July 15, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| C13ZZ | |
| ISIN | DE000CJ3SH91 |
| Date issued | 2019-02-15 |
| Strike | 6,469 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.475 € |
|---|---|
| Lowest since issue | 0.29 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
157.2
USD
Average target price
177.6
USD
Spread / Average Target
+13.00%
- Stock Market
- Certificates
- C13ZZ Certificat
